CCL24 and systemic sclerosis: CCL24 blockade with the monoclonal antibody CM-101 was reported to decrease SSc-serum induced dermal fibroblast-to-myofibroblast differentiation in vitro and to prevent experimental dermal and pulmonary fibrosis [204].